Skip to main content
European Respiratory Review logoLink to European Respiratory Review
. 2015 Sep;24(137):545. doi: 10.1183/09059180.50011514

“Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis.” Vincent Cottin and Toby Maher. Eur Respir Rev 2015; 24: 58–64.

PMCID: PMC9487684  PMID: 26324819

Unfortunately, there was a typographic error in this article. The sentence that read:

The mean daily dose of pirfenidone for all subjects during this time was 2332 mg·day−1, with the maximum possible daily dose being 2403 mg·day−1.

should have read as follows:

The mean daily dose of pirfenidone for all subjects during this time was 2070 mg·day−1, with the maximum possible daily dose being 2403 mg·day−1.

The online version of the article has been amended to reflect this correction.


Articles from European Respiratory Review are provided here courtesy of European Respiratory Society

RESOURCES